Z-1-Methoxy-2-pentene

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Z-1-Methoxy-2-pentene
• 英文别名: (Z)-1-methoxypent-2-ene
• 化学式: C₆H₁₂O
• 分子量: 100.16
• InChiKey: YCVHIAQANWEUFE-PLNGDYQASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  7
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS<br/>[FR] ACTIVATEUR D'INHIBITEURS DE L'HOMOLOGUE 2 DE ZESTE
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2014195919A1

  公开（公告）日：2014-12-11

  This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

  这项发明涉及到按照式（I）的新化合物，这些化合物是增强子Zeste同源物2（EZH2）的抑制剂，以及含有它们的药物组合物，它们的制备方法，以及它们在治疗癌症方面的用途。
• [EN] MACROCYCLES AS PIM INHIBITORS<br/>[FR] MACROCYCLES EN TANT QU'INHIBITEURS DE PIM
  申请人：AMGEN INC

  公开号：WO2014022752A1

  公开（公告）日：2014-02-06

  The invention relates to compounds of formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  该发明涉及式（1）的化合物及其盐。在某些实施例中，该发明涉及Pim-1和/或Pim-2以及/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，该发明涉及包含本文所披露的化合物的药物组合物，以及它们在预防和治疗与Pim激酶相关的疾病和病症，尤其是癌症中的用途。
• CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS
  申请人：Donde Yariv

  公开号：US20070112051A1

  公开（公告）日：2007-05-17

  A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.

  本文披露了一种含有所述详细描述的基团的化合物或其药学上可接受的盐或前药。本文还披露了包括所述衍生物或其药学上可接受的盐、四唑或所述衍生物的前药的化合物。所述衍生物在本文中有详细描述。本文还披露了治疗疾病或病症的方法，包括青光眼和眼压升高。还披露了相关药物的组成和制造方法。
• 10-HYDROXY-11-DIHYDROPROSTAGLANDIN ANALOGS AS SELECTIVE EP4 AGONISTS
  申请人：Donde Yariv

  公开号：US20070010495A1

  公开（公告）日：2007-01-11

  A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, wherein the dashed line represents the presence or absence of a double bond; J is C═O or CHOH; A is —(CH 2 ) 6 -, or cis —CH 2 CH═CH—(CH 2 ) 3 -, wherein 1 or 2 carbons may be substituted with S or O; B is CO 2 H, or CO 2 R, CONR 2 , CONHCH 2 CH 2 OH, CON(CH 2 CH 2 OH) 2 , CH 2 OR, P(O)(OR) 2 , CONRSO 2 R, SONR 2 , or R is H, C 1-6 alkyl; D is —(CH 2 ) n -, —X(CH 2 ) n , or —(CH 2 ) n X-, wherein n is from 0 to 3 and X is S or O; and E is an aromatic or heteroaromatic moiety having from 0 to 4 substituents, said substituents each comprising from 1 to 6 non-hydrogen atoms is disclosed herein. Methods, compositions, and medicaments related thereto, as well as experimental results showing prostaglandin EP4 selective agonist activity for certain compounds disclosed herein, are also disclosed.

  本文披露了一种化合物或其药学上可接受的盐或前药，其中虚线表示有无双键；J为C═O或CHOH；A为—（CH2）6-，或顺式—CH2CH═CH—（CH2）3-，其中1或2个碳原子可以被S或O取代；B为CO2H，或CO2R，CONR2，CONHCH2CH2OH，CON（CH2CH2OH）2，CH2OR，P（O）（OR）2，CONRSO2R，SONR2，或R为H，C1-6烷基；D为—（CH2）n-，—X（CH2）n，或—（CH2）nX-，其中n为0到3，X为S或O；E为具有0到4个取代基的芳香或杂环芳基，所述取代基每个包含1到6个非氢原子。本文还披露了与之相关的方法、组合物和药物，以及实验结果，显示了某些本文披露的化合物的前列腺素EP4选择性激动剂活性。
• Imidazolyl derivatives
  申请人：Thurieau Alain Christophe

  公开号：US20070032653A1

  公开（公告）日：2007-02-08

  The present invention is directed to imidazolyl derivatives of formula (I) where the substituents are defined in the specification, which are useful as agonists or antagonists of somatostatin receptors.

  本发明涉及公式（I）的咪唑基衍生物，其中置换基在说明书中定义，可用作生长抑素受体的激动剂或拮抗剂。